

*"Manufacturing authorization system
for production of medicinal products
for human use in India"*

*GAURAV KUMAR
Deputy Drugs Controller (India)
CDSCO, Govt. of India*

GMP

**10th PAN-RUSSIAN
GMP CONFERENCE**



DRUGS REGULATION

- ❖ *Drugs fall under the Concurrent List of the Constitution of India.*
- ❖ *Drugs & Cosmetics Act is a Central Act enforced by both Central and State Governments.*
- ❖ *Extended to Whole of India*

Background



- *Federal structure, enforced by both, Central and State authority*
 - *Central - CDSCO*
 - *State/UT Drug Control Authorities (28 STATES + 8 UT DCAs)*
- *Drugs and Cosmetics Act, 1940*
 - *Drugs Rules*
 - *Medical Devices Rules, 2017*
 - *New Drugs And Clinical Trial Rules, 2019*
 - *Cosmetics Rules, 2020*
- *Import, Manufacture, Sale and Distribution of Drugs, Cosmetics, Medical Devices, Vaccines, Veterinary medicines, blood and blood products etc.*
- *Export, through various guidelines and administrative orders*



CDSCO

New Drugs

Clinical Trials

Vaccines

Medical Devices (C & D)

All Import and Registration

Amendments to Rules

International cooperation

WC

Export NOC

STATE/UT

Manufacturing license.

Sale and Distribution

Medical Devices (A & B)

JOINT

LVP, Blood Centres

Joint Inspections

Sampling and Testing

Prosecutions

WHO-GMP

What Do We Regulate



- Drugs
(New Drugs, FDCs, Vaccines,
LVPs, r-DNA, Regenerative
medicines)

- Cosmetics

- Medical Devices and In-vitro
Diagnostics

- Blood Banks and Blood
Products
- LVPs

- Clinical Trials
- Ethics Committee
- Clinical site registration

- Subordinate Legislations
(Rules, Regulations,
Guidances, orders)

- Veterinary Drugs
- Phyto-pharmaceuticals
- Radiopharmaceuticals


- Import
- Export
- International Collaborations





Head Quarters	Regional Offices
New Drugs (New Drugs, IND, SND, FDC)	CoPP (WHO-GMP Scheme) (For export registration)
Global Clinical Trials (IND, NCE, NBE, New Drugs)	Import and Export (Through notified port offices)
Biologicals (Vaccines, r-DNA, NBE, Regenerative medicines, Blood centres and Blood products)	Laboratory Inspections (Approved Testing Laboratories)
Medical Devices (Market authorizations for Class C&D)	NOC for Export (Unapproved, and banned drugs)
Clinical Site Registrations	Sampling (To ascertain the quality of Drugs, Cosmetics and Medical Devices)
Import and Registration (Drugs, Cosmetics, Biologicals, Medical Devices)	Joint Inspections (Including Vaccines, r-DNA, LVPs and Blood Centre)

Scheme of Drug Regulations



Manufacturing Authorization:



- *Legal permission* - To manufacture drug products
 - Issued by State Licensing Authority
- *Manufacturers* shall comply with the provisions of the Act and of the Rules including GMP
- As per the Drugs Rules license are granted under various *Schedules* for Import, Manufacture, Sale and Distribution of drugs i.e. which specifies the requirements for
 - *Biological and Special Products,*
 - *Blood Centers,*
 - *Ophthalmic Preparations,*
 - *Narcotic and habit forming Drugs*
 - *Patent & Proprietary medicines,*
 - *Disinfectants fluids etc*
- *Validates* - the manufacturer's capability to produce safe and effective drugs



Drugs and Cosmetics Act and Rules provides

- *Legal provisions authorizing the inspectorate to inspect and enforce GXP throughout the supply chain are specified in Section 22 (Power of Inspector) of Drugs & Cosmetics Act,*
- *Rule 51 - Duties of Inspectors of premises licensed for sale,*
- *Rule 52- Duties of Inspectors specially authorized to inspect the manufacture of drugs,*
- *Rule 78 & 78A - Specifies various conditions of license which also includes the provision for inspection of the manufacturing premises.*
- *Rule 79 - Specifies inspection of manufacturing site before grant of license.*

Regulation on inspection



GMP and Requirements of Premises, Plant and Equipment for Pharmaceutical Products

<i>Part I</i>	<i>Good Manufacturing Practices for pharmaceutical products: Main principles</i>
<i>Following Parts provides specific requirements for manufacture of</i>	
<i>Part II</i>	<i>Sterile products, parenteral Preparations (small volume injectables and large volume parenteral) and Sterile ophthalmic preparations</i>
<i>Part III</i>	<i>Pharmaceutical products containing hazardous substances-Steroids , Sex hormones, cytotoxic substances etc</i>
<i>Part IV</i>	<i>Biological products</i>
<i>Part V</i>	<i>Radiopharmaceutical Products</i>
<i>Part VI</i>	<i>Phytopharmaceuticals</i>
<i>Part VII</i>	<i>Investigational Pharmaceutical products for clinical trials in humans</i>
<i>Part VIII</i>	<i>Oral dosage forms (tablets and capsules)</i>
<i>Part IX</i>	<i>Oral Liquids (syrups, elixirs, emulsions and suspensions)</i>
<i>Part X</i>	<i>Topical products (external preparations)</i>
<i>Part XI</i>	<i>Metered- dose- inhalers</i>
<i>Part XII</i>	<i>Active pharmaceutical Ingredients</i>
<i>Part XIII</i>	<i>Plant and equipment</i>

Summary



- *Regulation is established in India through a system of licensing and inspection*
- *There are joint responsibilities of CDSCO and State regulators for licensing and inspection of all drugs, biologicals including vaccines.*
- *Joint inspections with State licensing authorities for grant of licence and periodic inspections.*
- *Risk-based inspection is mandated in the Rules*
- *The manufacturer has to comply with the requirements of GMP and Requirements of Premises, Plant and Equipment for Pharmaceutical*
- *Marketers are also made responsible for ensuring quality of the pharmaceutical products marketed by them around the world.*
- *QR code/Bar code on all APIs and top 300 brands of formulations.*

